News
European regulatory body recommends suspension of rosiglitazone
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5291 (Published 24 September 2010) Cite this as: BMJ 2010;341:c5291
Related articles
- News Published: 24 September 2010; BMJ 341 doi:10.1136/bmj.c5287
- News Published: 29 September 2010; BMJ 341 doi:10.1136/bmj.c5333
- News Published: 24 January 2011; BMJ 342 doi:10.1136/bmj.d488
- News Published: 29 June 2011; BMJ 342 doi:10.1136/bmj.d4105
- News Published: 13 March 2012; BMJ 344 doi:10.1136/bmj.e2002
- News Published: 01 February 2013; BMJ 346 doi:10.1136/bmj.f695
- Observations Published: 22 August 2013; BMJ 347 doi:10.1136/bmj.f5140
See more
- Sixty seconds on . . . 10 000 stepsBMJ March 08, 2024, 384 q598; DOI: https://doi.org/10.1136/bmj.q598
- Scarlett McNally: Enabling active travel can improve the UK’s healthBMJ March 06, 2024, 384 q522; DOI: https://doi.org/10.1136/bmj.q522
- Scarlett McNally: Boosting swimming for health and joyBMJ February 20, 2024, 384 q393; DOI: https://doi.org/10.1136/bmj.q393
- Variability in blood pressure could help predict heart attack and stroke risk, researchers sayBMJ February 09, 2024, 384 q363; DOI: https://doi.org/10.1136/bmj.q363
- Scarlett McNally: Preventing obesity is different from curing it—and even more urgentBMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134
Cited by...
- When EMA and FDA decisions conflict: differences in patients or in regulation?
- GSK fights compensation claims from UK patients who took rosiglitazone
- Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet
- Rosiglitazone and the need for a new drug safety agency